Logo image of ACTU

ACTUATE THERAPEUTICS INC (ACTU) Stock Fundamental Analysis

NASDAQ:ACTU - Nasdaq - US0050831009 - Common Stock - Currency: USD

6.75  -0.3 (-4.26%)

Fundamental Rating

0

ACTU gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. ACTU may be in some trouble as it scores bad on both profitability and health. ACTU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACTU has reported negative net income.
In the past year ACTU has reported a negative cash flow from operations.
ACTU Yearly Net Income VS EBIT VS OCF VS FCFACTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -564.49%, ACTU is not doing good in the industry: 96.77% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -564.49%
ROE N/A
ROIC N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACTU Yearly ROA, ROE, ROICACTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -5K -10K -15K -20K -25K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACTU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACTU Yearly Profit, Operating, Gross MarginsACTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, ACTU has more shares outstanding
ACTU has a better debt/assets ratio than last year.
ACTU Yearly Shares OutstandingACTU Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
ACTU Yearly Total Debt VS Total AssetsACTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

ACTU has an Altman-Z score of -53.44. This is a bad value and indicates that ACTU is not financially healthy and even has some risk of bankruptcy.
ACTU's Altman-Z score of -53.44 is on the low side compared to the rest of the industry. ACTU is outperformed by 93.73% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -53.44
ROIC/WACCN/A
WACCN/A
ACTU Yearly LT Debt VS Equity VS FCFACTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

ACTU has a Current Ratio of 0.46. This is a bad value and indicates that ACTU is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.46, ACTU is doing worse than 93.01% of the companies in the same industry.
A Quick Ratio of 0.46 indicates that ACTU may have some problems paying its short term obligations.
The Quick ratio of ACTU (0.46) is worse than 92.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.46
ACTU Yearly Current Assets VS Current LiabilitesACTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ACTU have decreased by -8.53% in the last year.
EPS 1Y (TTM)-8.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.54% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y57.91%
EPS Next 2Y22.67%
EPS Next 3Y11.54%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACTU Yearly EPS VS EstimatesACTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACTU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACTU Price Earnings VS Forward Price EarningsACTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACTU Per share dataACTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.67%
EPS Next 3Y11.54%

More info and screens

0

5. Dividend

5.1 Amount

ACTU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTUATE THERAPEUTICS INC

NASDAQ:ACTU (6/24/2025, 5:20:24 PM)

6.75

-0.3 (-4.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners53.53%
Inst Owner Change2.92%
Ins Owners4.88%
Ins Owner Change0%
Market Cap132.44M
Analysts82.22
Price Target27.79 (311.7%)
Short Float %1.34%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.49%
Min EPS beat(2)-11.56%
Max EPS beat(2)-3.43%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34%
PT rev (3m)36.23%
EPS NQ rev (1m)-15.66%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-16.33%
EPS NY rev (3m)-10.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -564.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.46
Quick Ratio 0.46
Altman-Z -53.44
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.65%
EPS Next Y57.91%
EPS Next 2Y22.67%
EPS Next 3Y11.54%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.01%
OCF growth 3YN/A
OCF growth 5YN/A